{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:25Z","timestamp":1792134865894,"version":"4.4.0"},"reference-count":11,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by limited treatment options and poor prognosis. Immune checkpoint blockade, particularly via programmed cell death protein-1\/programmed death-ligand 1 inhibition, has improved outcomes in selected patients with TNBC; however, resistance remains a major barrier. Recent studies have identified B7-H3 (CD276) as a key immune-suppressive molecule overexpressed in TNBC, correlating with poor prognosis and immune exclusion. Jiang\n                    <jats:italic>et al<\/jats:italic>\n                    demonstrate that B7-H3 inhibition triggers a compensatory metabolic adaptation in TNBC cells, marked by upregulation of fatty acid synthesis and \u03b2-oxidation, particularly via the AKT-SREBP1-FASN signaling axis. This metabolic reprogramming promotes survival and immune evasion, limiting the efficacy of B7-H3-targeted therapies. Dual inhibition of B7-H3 and fatty acid synthase synergistically enhances tumor cell apoptosis, suppresses proliferation and migration, and promotes CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell infiltration in vitro and in vivo. These findings reveal a novel immune-metabolic resistance mechanism in TNBC and provide a compelling rationale for combinatorial strategies targeting both immune checkpoints and metabolic pathways.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2025-013210","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:00:20Z","timestamp":1772031620000},"page":"e013210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Commentary on \u201cTargeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer\u201d"],"prefix":"10.1136","volume":"14","author":[{"given":"Nour","family":"Kotaich","sequence":"first","affiliation":[{"name":"UR7509, Universit\u00e9 de Reims Champagne-Ardenne, Reims, Grand Est, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Potteaux","sequence":"additional","affiliation":[{"name":"UR7509, Universit\u00e9 de Reims Champagne-Ardenne, Reims, Grand Est, France"},{"name":"D\u00e9partement de Recherche, Institut Godinot, Reims, France"},{"name":"Inserm, D\u00e9l\u00e9gation r\u00e9gionale Paris \u00cele-de-France Centre Nord, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026022507001210000_14.2.e013210.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-024-00618-6","article-title":"High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer","volume":"10","author":"Mei","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2026022507001210000_14.2.e013210.2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010924","article-title":"Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer","volume":"13","author":"Jiang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026022507001210000_14.2.e013210.3","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.bbrc.2016.12.021","article-title":"B7-H3 regulates lipid metabolism of lung cancer through SREBP1-mediated expression of FASN","volume":"482","author":"Luo","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2026022507001210000_14.2.e013210.4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1538"},{"key":"2026022507001210000_14.2.e013210.5","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12595","article-title":"B7\u2011H3 promotes the epithelial\u2011mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K\/AKT pathway","volume":"25","author":"Liao","year":"2022","journal-title":"Mol Med Rep"},{"key":"2026022507001210000_14.2.e013210.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.07.019"},{"key":"2026022507001210000_14.2.e013210.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.03.002"},{"key":"2026022507001210000_14.2.e013210.8","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.18632\/oncotarget.6902","article-title":"Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT\/mTOR inhibitors","volume":"7","author":"Nunes-Xavier","year":"2016","journal-title":"Oncotarget"},{"key":"2026022507001210000_14.2.e013210.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-024-00656-0","article-title":"Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion","volume":"10","author":"Serhan","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2026022507001210000_14.2.e013210.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33034-0","article-title":"Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6Chi monocytes and differentiation to pro-angiogenic myeloid cells","volume":"13","author":"Tran","year":"2022","journal-title":"Nat Commun"},{"key":"2026022507001210000_14.2.e013210.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2852"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:00:22Z","timestamp":1772031622000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/jitc-2025-013210"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013210","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}